尽管周二美股市场整体表现分化，Corbus Pharmaceuticals Holdings Inc.（CRBP）股价下跌3.59%至8.06美元，但其表现仍优于部分同业竞争对手。纳斯达克综合指数当日微涨0.18%至20677.80点，而道琼斯工业平均指数则下挫0.98%至44023.29点。
这家生物制药公司当前股价较7月31日创下的52周高点61.90美元已下跌86.98%。值得注意的是，在同行企业普遍走低的环境中，Corbus展现出相对韧性：Vanda Pharmaceuticals（VNDA）重挫4.23%至4.76美元，Fortress Biotech（FBIO）下跌1.02%至1.94美元，Viking Therapeutics（VKTX）亦下滑2.94%至30.70美元。
当日该股成交量仅为97,808手，较其50日平均成交量161,438手低出63,630手，交投活跃度明显减弱。最新行情数据显示，生物科技板块整体承压，但Corbus在横向对比中展现出相对抗跌特性。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.